Kitano Y, Hayashi H, Matsumoto T, Kinoshita S, Sato H, Shiraishi Y, et al. Borderline resectable for colorectal liver metastases: present status and future perspective. World J Gastrointest Surg. 2021;13:756–63.

Article  PubMed  PubMed Central  Google Scholar 

Giuliante F, Viganò L, De Rose AM, Mirza DF, Lapointe R, Kaiser G, et al. Liver-first approach for synchronous colorectal metastases: analysis of 7360 patients from the livermetsurvey registry. Ann Surg Oncol. 2021;28:8198–208.

Article  PubMed  PubMed Central  Google Scholar 

Schmoll H-J, Mann J, Meinert F, Garlipp B, Borchert K, Vogel A, et al. Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial. Br J Cancer. 2023;130:233–41.

Article  PubMed  PubMed Central  Google Scholar 

Shen C, Hu H, Cai Y, Ling J, Zhang J, Wu Z, et al. mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial. Ann Transl Med. 2022;10:171.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, et al. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: a report of five cases. Oncol Lett. 2016;12:3127–34.

Article  PubMed  PubMed Central  Google Scholar 

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508.

Article  CAS  PubMed  Google Scholar 

Scartozzi M, Vincent L, Chiron M, Cascinu S. Aflibercept, a new way to target angiogenesis in the second line treatment of metastatic colorectal cancer (mCRC). Target Oncol. 2016;11:489–500.

Article  PubMed  Google Scholar 

Kir G, Gurbuz A, Karateke A, Kir M. Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma. World J Gastrointest Surg. 2010;2:109–16.

Article  PubMed  PubMed Central  Google Scholar 

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422.

Article  PubMed  Google Scholar 

Sugiyama M, Uehara H, Shin Y, Shiokawa K, Fujimoto Y, Mano Y, et al. Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis. Surg Today. 2022;52:633–42.

Article  PubMed  Google Scholar 

Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.20.01225.

Article  PubMed  Google Scholar 

D’Hondt M, Lucidi V, Vermeiren K, Van Den Bossche B, Donckier V, Sergeant G. The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer. World J Surg Oncol. 2017;15:54.

Article  PubMed  PubMed Central  Google Scholar 

Lam VWT, Laurence JM, Pang T, Johnston E, Hollands MJ, Pleass HCC, et al. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB. 2014;16:101–8.

Article  PubMed  Google Scholar 

Watanabe J, Terazawa T, Yamane S, Kazama H, Uetake H, Yoshino T. Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance. Int J Clin Oncol. 2023;28:130–8.

Article  CAS  PubMed  Google Scholar 

Muro K, Salinardi T, Singh AR, Macarulla T. Safety of Aflibercept in metastatic colorectal cancer: a literature review and expert perspective on clinical and real-world data. Cancers. 2020. https://doi.org/10.3390/cancers12040844.

Article  PubMed  PubMed Central  Google Scholar 

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–506.

Article  PubMed  Google Scholar 

Ottaiano A, Capozzi M, Tafuto S, De Stefano A, De Divitiis C, Romano C, et al. Folfiri-aflibercept vs. folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice. Front Oncol. 2019;9:766.

Article  PubMed  PubMed Central  Google Scholar 

Fernández Montes A, Martínez Lago N, Covela Rúa M, de la Cámara GJ, González Villaroel P, Méndez Méndez JC, et al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med. 2019;8:882–9.

Article  PubMed  PubMed Central  Google Scholar 

Van Cutsem E, Paccard C, Chiron M, Tabernero J. Impact of prior bevacizumab treatment on VEGF-A and PlGF levels and outcome following second-line aflibercept treatment: biomarker post hoc analysis of the VELOUR trial. Clin Cancer Res. 2020;26:717–25.

Article  PubMed  Google Scholar 

Bellier J, De Wolf J, Hebbar M, Amrani ME, Desauw C, Leteurtre E, et al. Repeated resections of hepatic and pulmonary metastases from colorectal cancer provide long-term survival. World J Surg. 2018;42:1171–9.

Article  PubMed  Google Scholar 

Matsuishi K, Miyamoto Y, Hiyoshi Y, Tokunaga R, Imai K, Hayashi H, et al. Ongoing 5 year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer. Surg Case Rep. 2020;6:149.

Article  PubMed  PubMed Central  Google Scholar 

Heise D, Bayings W, Tuinhof A, Eickhoff R, Kroh A, Ulmer F, et al. Long-term outcome and quality of life after initial and repeat resection of colorectal liver metastasis: a retrospective analysis. Int J Surg. 2017;48:281–5.

Article  CAS  PubMed  Google Scholar 

Neeff HP, Drognitz O, Holzner P, Klock A, Bronsert P, Hopt UT, et al. Outcome after repeat resection of liver metastases from colorectal cancer. Int J Colorectal Dis. 2013;28:1135–41.

Article  PubMed  Google Scholar 

Erroi F, Scarpa M, Angriman I, Cecchetto A, Pasetto L, Mollica E, et al. Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy. J Surg Oncol. 2007;96:113–7.

Article  PubMed  Google Scholar 

Hishida T, Tsuboi M, Okumura T, Boku N, Ohde Y, Sakao Y, et al. Does repeated lung resection provide long-term survival for recurrent pulmonary metastases of colorectal cancer? results of a retrospective japanese multicenter study. Ann Thorac Surg. 2017;103:399–405.

Article  PubMed  Google Scholar 

Ozawa H, Kotake K, Kobayashi H, Kobayashi H, Sugihara K. Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database. Surg Today. 2014;44:1643–50.

Article  PubMed  Google Scholar 

Bang K, Kim JE, Kim TW, Kim SY, Lim S-B, Park IJ, et al. Clinical outcomes of curative surgical resection of peritoneal metastasis in patients with colorectal cancer: a long-term follow-up study. Cancer Med. 2023;12:2861–8.

Article  PubMed  Google Scholar